Loading…

Erythropoietin Resistance in Patients with Chronic Kidney Disease: Current Perspectives

Anemia is a frequent complication of chronic kidney disease, and its primary cause is erythropoietin defciency. After diagnosis, treatment begins with administration of an erythropoiesis-stimulating agent (ESA). However, some patients present with resistance to ESA, which needs to be reversed, as it...

Full description

Saved in:
Bibliographic Details
Published in:International journal of nephrology and renovascular disease 2020-01, Vol.13, p.231-237
Main Authors: Santos, Elton Jonh Freitas, Dias, Raimunda Sheyla Carneiro, Lima, Janielle Ferreira de Brito, Filho, Natalino Salgado, dos Santos, Alcione Miranda
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anemia is a frequent complication of chronic kidney disease, and its primary cause is erythropoietin defciency. After diagnosis, treatment begins with administration of an erythropoiesis-stimulating agent (ESA). However, some patients present with resistance to ESA, which needs to be reversed, as it can increase the risk of death in patients with kidney disease. Therefore, we provide a discussion of the current literature regarding the factors that can modify the response to this class of drugs and the strategies that can be considered to optimize the benefts of treating anemia. Keywords: anemia, chronic kidney disease, erythropoietin, drug resistance
ISSN:1178-7058
1178-7058
DOI:10.2147/IJNRD.S239151